Objective: To examine the outcome of orchidectomy following primary chemotherapy in patients with metastatic testicular cancer. Patients and Methods: This was a retrospective analysis of patients who underwent primary chemotherapy without initial orchidectomy for testicular cancer between 1982 and 2006. The patients were identified from the regional oncology cancer database in our tertiary referral hospital. Their case notes were reviewed regarding initial presentation, chemotherapy, clinical progress and pathological outcomes following surgery. Results: 21 evaluable patients were identified (14 non-seminomatous germ cell tumours, 7 seminomas). 16 patients underwent standard orchidectomy within 12 months of commencing chemotherapy and 5 patients underwent significantly delayed orchidectomy (19-68 months, mean 45.1 months). Orchidectomy in the standard group showed tumour necrosis or a scar in 13 patients (81%) and differentiated or mature teratoma in 3 patients associated with bulky poorly responsive retroperitoneal disease (19%). In the delayed orchidectomy group 3 out of 5 patients had viable seminoma, of which two were associated with carcinoma in situ. Conclusion: Our study raises concerns as regards a potentially high risk of late tumour development in testes which are preserved following apparent tumour resolution after chemotherapy.

Keywords:
Testicular cancer, Seminoma, Teratoma, Germ cell tumour, Chemotherapy, Orchidectomy, Histopathology, Tumour recurrence
1.
Fung C, Vaughn DJ: Complications associated with chemotherapy in testicular cancer management. Nat Rev Urol 2011;8:213-222.
2.
Ramani VA, Grey BR, Addla SK, et al: Histological outcome of delayed orchidectomy after primary chemotherapy for metastatic germ cell tumour of the testis. Clin Oncol (R Coll Radiol) 2008;20:247-252.
3.
Geldart TR, Simmonds PD, Mead GM: Orchidectomy after chemotherapy for patients with metastatic germ cell cancer. BJU Int 2002;90:451-455.
4.
Ondrus D, Hornák M, Breza J, et al: Delayed orchiectomy after chemotherapy in patients with advanced testicular cancer. Int Urol Nephrol 2001;32:665-667.
5.
Leibovitch I, Little JS Jr, Foster RS, et al: Delayed orchiectomy after chemotherapy for metastatic nonseminomatous germ cell tumors. J Urol 1996;155:952-954.
6.
Oliver RT, Ong J, Blandy JP, Altman DG: Testis conservation studies in germ cell cancer justified by improved primary chemotherapy response and reduced delay, 1978-1994. Br J Urol 1996;78:119-124.
7.
Bottomley D, Fisher C, Hendry WF, et al: Persistent carcinoma in situ of the testis after chemotherapy for advanced testicular germ cell tumours. Br J Urol 1990;66:420-424.
8.
Chong C, Logothetis CJ, von Eschenbach A, et al: Orchiectomy in advanced germ cell cancer following intensive chemotherapy: a comparison of systemic and testicular response. J Urol 1986;136:1221-1223.
9.
Greist A, Einhorn LH, Williams SD, et al: Pathologic findings at orchidectomy following chemotherapy for disseminated testicular cancer. J Clin Oncol 1984;2:1025-1027.
10.
Albers P (chairman), Albrecht W, Algaba F, et al: Guidelines on Testicular Cancer. European Association of Urology 2008. http://www.uroweb.org/fileadmin/user_upload/Guidelines/09%20Testicular%20Cancer.pdf.
11.
Dieckmann KP, Loy V: Intratesticular effects of cisplatin-based chemotherapy. Eur Urol 1995;28:25-30.
12.
Oliver RT, Ong J, Berney D, et al: Testis conserving chemotherapy in germ cell cancer: its potential to increase understanding of the biology and treatment of carcinoma-in-situ. APMIS 2003;111:86-91; discussion 91-92.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.